Lumipulse^® G ADxPLORER^® α-Synuclein

Despite the limited utility reported for α-synuclein as a diagnostic biomarker for Parkinson’s disease, this presynaptic protein remains a central pathological feature of synucleinopathies and is also implicated in Alzheimer’s disease where increased levels may indicate synaptic damage¹. As a marker linked to synaptic dysfunction and/or loss across neurodegenerative disorders, α-synuclein therefore continues to be investigated for potential prognostic and disease-monitoring applications².

The Lumipulse® G ADxPLORER® α-Synuclein assay was developed using two proprietary monoclonal antibodies. The ADx305 mAb (90574) serves as the capture antibody, combined with an alkaline phosphatase-conjugated Fab fragment derived from the ADx301 mAb (90572), which targets the unique α-synuclein region. The assay is calibrated using full-length recombinant α-synuclein protein.
 

References:

1. Bellomo et al. Phosphorylated α-synuclein in CSF and plasma does not reflect synucleinopathy. NPJ Parkinsons Dis. 2025 Aug 7; 11(1):232.
2. Berman et al. Current Status of α-Synuclein Biomarkers and the Need for α-Synuclein PET Tracers. Cells. 2025 Aug 18;14(16):1272.

Lumipulse is a registered trademark of Fujirebio Inc.
ADxPLORER is a registered trademark of Fujirebio Europe NV.